EU vs US Sunscreen Regulation: SPF Testing, Approved Filters & Compliance Guide | Onerchem
◆ UV Filters · Regulatory
EU vs US Sunscreen Regulation: SPF Testing, Approved Filters & What Changes When You Cross Markets
The EU and US regulate sunscreens from fundamentally different legal starting points — one treats them as cosmetics, the other as drugs. This single difference cascades into divergent approved filter lists, different SPF testing requirements, different UVA standards, and different labelling rules. This guide covers the practical implications for formulators working across both markets.
The fundamental difference — cosmetic vs drug
Every practical difference between EU and US sunscreen regulation flows from one foundational distinction: the regulatory category.
European Union
Sunscreens = Cosmetic Products
Legal framework
Regulation (EC) No 1223/2009 — the EU Cosmetics Regulation. UV filters listed in Annex VI.
Pre-market approval
No pre-market approval required. Manufacturer responsible for safety and compliance. Product Information File (PIF) required.
New UV filter pathway
Annex VI amendment via European Commission — scientific assessment by SCCS (Scientific Committee on Consumer Safety). Faster than US OTC pathway historically.
Number of approved UV filters
28+ UV filter actives listed in Annex VI as of the current Regulation text. Source ↗
UVA requirement
Commission Recommendation 2006/647/EC — UVA-PF should be at least 1/3 of labelled SPF. Not legally binding under the Regulation but de facto industry standard.
United States
Sunscreens = OTC Drug Products
Legal framework
21 CFR Parts 201 and 352 — FDA OTC drug monograph system. UV filters listed in the OTC monograph.
Pre-market approval
No individual pre-market approval for monograph-compliant products. But formula must comply with OTC monograph exactly — no deviation permitted.
New UV filter pathway
Sunscreen Innovation Act (2014) pathway — requires full safety and efficacy data package to FDA. Multiple EU-approved filters pending FDA review for years without resolution.
Number of approved UV filters
16 UV filter actives in the OTC monograph, of which only 2 (zinc oxide and titanium dioxide) are considered GRASE (Generally Recognized as Safe and Effective) by FDA's 2019 proposed rule. FDA ↗
UVA requirement
FDA requires broad spectrum testing per FDA's in vitro test method (Critical Wavelength ≥370nm) for any product making a "broad spectrum" claim. No UVA-PF ratio requirement analogous to the EU.
The US OTC drug framework was not designed for the pace of cosmetic ingredient innovation. The result is a system where UV filters with strong EU safety records and years of market use cannot be sold as sunscreen actives in the US — not because they have been found unsafe, but because the approval pathway has not been completed.
SPF testing methods — ISO 24444 vs FDA method
EU — ISO 24444
In vivo · Human Volunteers
Standard
ISO 24444:2019 — Cosmetics, Sun protection test methods, In vivo determination of the sun protection factor (SPF).
Application dose
2 mg/cm² application dose — the international standard application rate for SPF testing.
Minimum panellists
10 evaluable subjects required per ISO 24444:2019.
Result expression
SPF value with confidence interval. Labelled SPF categories: 6, 10, 15, 20, 25, 30, 50, 50+ per Cosmetics Europe labelling guidance.
Status
De facto EU standard, referenced in Commission Recommendation 2006/647/EC. Accepted across EU, GCC, Australia, and most Asian markets.
US — FDA SPF Test
In vivo · 21 CFR 201.327
Standard
21 CFR 201.327 — FDA's OTC sunscreen SPF test procedure.
Application dose
2 mg/cm² — same application dose as ISO 24444.
Minimum panellists
20 evaluable subjects required — more than ISO 24444.
Result expression
SPF value. Labelled as the tested SPF value (e.g., SPF 30, SPF 50). No standardised category system equivalent to the EU labelling guidance.
Mutual recognition
ISO 24444 results are generally accepted as equivalent by FDA for products tested at the same application dose and panel size, though the FDA method remains the formally specified standard.
Practical Note on SPF Testing
The core SPF test methodology (in vivo, 2 mg/cm², UV irradiation to determine MED) is substantially similar between ISO 24444 and the FDA method. The main practical differences are panel size (10 vs 20 evaluable subjects) and result rounding conventions. Many contract testing laboratories conduct tests that satisfy both standards simultaneously, reducing the cost of dual-market testing. Confirm with your testing laboratory which standard their protocol is designed to meet.
UVA requirements — the most significant practical divergence
The treatment of UVA protection is where EU and US regulation diverges most significantly for formulators.
EU — UVA-PF ratio requirement
Under Commission Recommendation 2006/647/EC, sunscreen products making an SPF claim should also provide UVA protection with a UVA-PF of at least one-third of the labelled SPF value. This means:
- SPF 15 product → UVA-PF should be ≥5
- SPF 30 product → UVA-PF should be ≥10
- SPF 50 product → UVA-PF should be ≥16.7
Products meeting the ratio requirement may carry the UVA circle logo (a circle with "UVA" inside). This is a Commission Recommendation rather than a binding legal requirement under the Cosmetics Regulation — but it has been widely adopted as the de facto industry standard and is expected by EU retailers and consumers. UVA-PF is typically determined by ISO 24443 (in vitro) or ISO 24442 (in vivo).
US — Broad Spectrum critical wavelength test
The US FDA does not require a UVA-PF ratio. Instead, products wishing to make a "Broad Spectrum" label claim must pass the FDA's in vitro critical wavelength test, which requires a critical wavelength of ≥370nm. 21 CFR 201.327 ↗
Why This Matters for Formulation
The EU's UVA-PF ratio requirement is more demanding than the US critical wavelength test in practical terms. A formula can pass the US broad spectrum test with relatively modest UVA-I coverage, while the EU requirement forces meaningful UVA-I protection relative to the SPF level. This is one reason why Avobenzone — which provides deep UVA-I coverage at 360nm — plays a more central role in EU-targeted formulas than in many US formulas, where TiO₂ and Octinoxate systems can pass broad spectrum testing without strong UVA-I absorption.
Photostability testing — why Avobenzone formulas fail here
Photostability testing is required for any EU sunscreen making SPF or UVA claims. The test protocol, specified within ISO 24443, measures the change in UVA protection factor before and after simulated UV irradiation. This is the step where Avobenzone-containing formulas most commonly fail during development.
The ISO 24443 photostability protocol
- Step 1 — Apply to PMMA plate at 1.3 mg/cm² — The sunscreen is applied to a roughened polymethylmethacrylate (PMMA) plate that mimics skin surface texture. The transmittance spectrum (290–400 nm) is measured to establish the pre-irradiation UVA PF.
- Step 2 — Irradiate with defined UV dose — The plate is exposed to a calibrated solar simulator delivering approximately 1.2 MEDs — representing realistic real-world UV exposure. This is the "UV challenge" that degrades photolabile filters like Avobenzone.
- Step 3 — Re-measure transmittance — The 290–400 nm spectrum is measured again after irradiation. The post-irradiation UVA PF is calculated from this measurement.
- Step 4 — Pass criteria — The formula passes if: (1) post-irradiation UVA PF is still ≥ SPF/3, and (2) critical wavelength remains ≥ 370 nm after irradiation. A formula that passes initial UVA criteria but fails photostability cannot use the UVA logo or "broad spectrum" language — regardless of its SPF value.
Common Failure Pattern
The most frequent photostability failure in Avobenzone-containing formulas is a post-irradiation UVA PF that drops below the SPF/3 threshold — even when the pre-irradiation result passes. The fix is almost always increasing the photostabiliser:Avobenzone ratio (Octocrylene in US formulas, DHHB in EU formulas), or switching to a more effective photostabiliser. DHHB-based formulas very rarely fail photostability because the UVA filter itself does not degrade under irradiation.
Water resistance testing — optional but commercially expected
Water resistance is a separate, optional claim requiring testing per ISO 16474 or DIN 67502. The formula must retain ≥50% of its SPF after two 20-minute water immersions. The critical commercial detail most brands miss: the labelled SPF for a water-resistant product must be the post-immersion value, not the pre-immersion value. A formula tested at SPF 50 dry but retaining only SPF 25 after immersion must be labelled SPF 25 (Medium) if marketed as water resistant.
Prohibited Claims in the EU
The Commission Recommendation explicitly discourages "sunblock," "total protection," and "100% protection" — no cosmetic sunscreen provides complete UV blockage. "All-day protection" is also not supported by any current photostability or substantivity data. Brands using these terms in EU markets risk regulatory challenge and consumer trust issues.
Approved UV filter comparison — the filters that create dual-market problems
The following table shows the UV filters most relevant to B2B formulators, particularly those that are approved in the EU but not the US — the most common source of dual-market formulation challenges.
| UV Filter | EU Status (Annex VI) | US Status (OTC Monograph) | Max % (EU) |
|---|---|---|---|
| Avobenzone (Butyl Methoxydibenzoylmethane) | Approved | Approved (max 3%) | 5% |
| Zinc Oxide | Approved | GRASE per FDA 2019 proposed rule | 25% |
| Titanium Dioxide | Approved | GRASE per FDA 2019 proposed rule | 25% |
| Octinoxate (Ethylhexyl Methoxycinnamate) | Approved | Approved (max 7.5%) | 10% |
| Octocrylene | Approved | Approved (max 10%) | 10% |
| DHHB (Diethylamino Hydroxybenzoyl Hexyl Benzoate) | Approved | Not approved | 10% |
| Bemotrizinol (Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) | Approved | Not approved (pending since 2005) | 10% |
| Bisoctrizole (Methylene Bis-Benzotriazolyl Tetramethylbutylphenol) | Approved | Not approved (pending since 2005) | 10% |
| Drometrizole Trisiloxane (Mexoryl XL) | Approved | Not approved | 15% |
| Homosalate | Approved | Under review — FDA requested additional data in 2021 | 10% |
Sources: EU Regulation (EC) No 1223/2009, Annex VI · FDA Sunscreen OTC Drug Products · 21 CFR Part 352
Critical Note on FDA 2019 Proposed Rule
In 2021, the FDA issued a proposed rule stating that only zinc oxide and titanium dioxide are GRASE (Generally Recognized As Safe and Effective) among OTC sunscreen actives, while 12 others (including common filters like oxybenzone, octinoxate, homosalate, and octocrylene) were classified as needing more data. This proposed rule has not been finalised as of the time of writing. The OTC monograph system continues to permit these 12 filters for use — but the FDA's GRASE classification uncertainty has created regulatory and commercial complexity. Formulators should confirm the current status of specific filters with a regulatory specialist before launch. FDA ↗
Labelling differences
EU Labelling
Cosmetics Regulation + Cosmetics Europe Guidelines
SPF categories
Cosmetics Europe recommends standardised categories: Low (6, 10), Medium (15, 20, 25), High (30, 50), Very High (50+). The tested SPF value must equal or exceed the labelled category value.
UVA logo
UVA circle logo permitted if UVA-PF ≥ SPF/3. Not mandatory but commercially expected.
Ingredient list
INCI names in descending order of weight, per EU Cosmetics Regulation Annex I.
Drug facts panel
Not required — sunscreens are cosmetics, not drugs in the EU.
"Broad spectrum"
Not a defined regulatory term in EU labelling — UVA-PF ratio and UVA logo serve the equivalent function.
US Labelling
FDA OTC Drug Labelling Requirements
SPF categories
No standardised category system — labelled as tested SPF value (SPF 15, SPF 30, SPF 50, etc.). SPF above 50 was proposed to be labelled as "SPF 50+" in FDA's 2019 proposed rule, pending finalisation.
UVA logo
No UVA logo system equivalent to EU.
Ingredient list
Drug Facts panel required. Active ingredients listed first (UV filters as OTC drug actives), then inactive ingredients in alphabetical order.
Drug facts panel
Mandatory — includes active ingredients, uses, warnings, directions, other information, inactive ingredients. Format specified in 21 CFR 201.327.
"Broad spectrum"
Defined regulatory claim — permitted only if the product passes the FDA critical wavelength test (≥370nm). Products not passing cannot use this term.
Formulating for both EU and US markets
Dual-market sunscreen development is one of the more complex formulation challenges in cosmetic chemistry. The UV filter list divergence means that a single formula rarely satisfies both markets without modification.
- Start with the more restrictive market — the US OTC list — If you need to sell in the US, your UV filter selection is constrained to the OTC monograph list. Design the US formula first using only approved actives, then adapt for the EU by adding or substituting filters that are EU-approved but not US-approved (DHHB, Bemotrizinol, Bisoctrizole). This is easier than designing for the EU first and then trying to retrofit US compliance.
- Avobenzone + Octocrylene for US market photostability — Since DHHB is not FDA-approved, Octocrylene is the practical Avobenzone photostabiliser for US market formulas. Octocrylene is approved in both EU and US, making it usable in a shared base formula that can be adapted for both markets.
- Avobenzone + DHHB for EU-only formulas — For EU, GCC, and Asian market formulas where US OTC compliance is not required, DHHB is the superior photostabiliser — it provides UVA coverage that Octocrylene does not, helping meet the EU UVA-PF ratio requirement. See DHHB Formulation Guide.
- Run market-specific SPF and UVA testing — ISO 24444 for EU/global markets, FDA method compliance for US. The critical wavelength test for US "Broad Spectrum" claim. ISO 24443 for EU UVA-PF determination and photostability validation.
- US product registration and labelling are different pipeline — US sunscreens require Drug Facts panel, OTC monograph compliance review, and specific claims management as OTC drug products. This is a regulatory affairs function, not just a formulation function. Engage a US regulatory specialist for US market launch.
- Monitor FDA's OTC monograph rulemaking — The FDA's 2019 proposed rule and subsequent updates have left the status of several common UV filters uncertain. The situation may change. Confirm the current regulatory status of any UV filter with a regulatory specialist before committing to a US-market formula. FDA ↗
Formulation Guide · UV Filters
Hybrid SPF30 Sunscreen — Complete formula with Avobenzone + DHHB photostabilisation system for EU market
View Guide
→
Frequently asked questions
In the EU, sunscreens are cosmetic products under Regulation (EC) No 1223/2009 — no pre-market approval, manufacturer-responsible compliance, UV filters in Annex VI. In the US, sunscreens with SPF claims are OTC drug products under FDA authority — must comply with the OTC monograph (21 CFR Parts 201 and 352), which lists approved UV filter actives at approved concentrations. The OTC drug framework creates a much slower pathway for new UV filters, which is why the US-approved filter list is significantly shorter than the EU list.
ISO 24444:2019 is the de facto EU standard for SPF determination, referenced in Commission Recommendation 2006/647/EC. It is an in vivo method using a minimum of 10 evaluable subjects at 2 mg/cm² application dose. The EU Cosmetics Regulation (EC) No 1223/2009 does not mandate a specific test method by name, but ISO 24444 is universally accepted across EU member states and by EU retailers. Source: ISO 24444:2019.
Not legally mandatory under the Cosmetics Regulation itself, but Commission Recommendation 2006/647/EC specifies that SPF-labelled sunscreens should provide a UVA-PF of at least 1/3 of the labelled SPF. This has become the de facto industry standard across EU markets. Products meeting the ratio may carry the UVA circle logo. Source: Commission Recommendation 2006/647/EC.
Because US sunscreens are regulated as OTC drugs, new UV filter actives require FDA OTC approval — a significantly more resource-intensive pathway than the EU Annex VI amendment process. Several EU-approved filters (DHHB, Bemotrizinol, Bisoctrizole) have been submitted for FDA review under the Sunscreen Innovation Act (2014) but have not received approval, partly due to FDA requests for additional data. The EU cosmetic ingredient pathway has historically been faster for UV filter actives with strong safety profiles.
Rarely, without modification. The UV filter list divergence typically requires separate formulas — most EU-approved filters that enhance performance (DHHB, Bemotrizinol, Bisoctrizole) are not in the US OTC monograph. A practical approach: design the US formula first using only OTC monograph-approved filters (Avobenzone + Octocrylene for photostability), then develop the EU variant substituting DHHB for Octocrylene to improve UVA-I coverage and photostability. The two formulas can share the same emulsion base and non-UV-filter actives.